GlassScriptPhysician profile
Susan M Davy
NPI 1598704215
$3,237.68
in general payments reported to CMS, 2019-2025
33 companies · $457 in 2025
The $457 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $163 · 2021: $505 · 2022: $617 · 2023: $793 · 2024: $481 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,546 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,546.22 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $394.61 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $355.28 | 2023-2025 | Veozah |
| Aspira Women'S Health INC | $325.36 | 2021-2023 | Ova1 |
| Mayne Pharma Commercial LLC | $287.23 | 2021-2025 | |
| Biogen, INC. | $178.66 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $177.09 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $136.27 | 2019-2025 | Slynd |
| Minerva Surgical, INC | $134.06 | 2022-2023 | |
| Organon LLC | $127.86 | 2021-2025 | Nexplanon |
| Agile Therapeutics, INC. | $114.70 | 2021-2024 | Twirla |
| Exact Sciences Corporation | $103.40 | 2023-2025 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $92.93 | 2019-2022 | |
| Hologic Sales and Service, LLC | $85.28 | 2019-2023 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Mylan Pharmaceuticals INC. | $71.70 | 2021-2022 | |
| Gynesonics, INC. | $66.06 | 2024-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $61.33 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.01 | 2020-2024 | |
| Evofem Biosciences, INC. | $58.03 | 2021 | |
| Pfizer INC. | $46.33 | 2021-2024 | |
| Millicent US INC | $40.95 | 2025 | Femlyv |
| Merck Sharp & Dohme LLC | $40.18 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $39.74 | 2024 | Exparel, Zilretta, Iovera |
| Lupin INC. | $32.50 | 2019 | |
| Optumhealth Care Solutions, LLC | $30.58 | 2023-2024 | Eitan Medical, Vivify Health Care Team Portal 001, Zyno Solutions |
| Shield Therapeutics INC | $29.27 | 2025 | |
| Amag Pharmaceuticals, INC. | $28.31 | 2019-2020 | |
| Medical Device Business Services, INC. | $21.28 | 2025 | Harmonic |
| Becton, Dickinson and Company | $21.00 | 2024 | Bd Onclarity |
| Myovant Sciences INC. | $20.66 | 2021 | |
| Medicem INC. | $17.48 | 2022 | |
| Smith+Nephew, INC. | $15.00 | 2024 | Pico 7 |
| Sumitomo Pharma America, INC. | $14.25 | 2024 | Myfembree |
| Meditrina | $11.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Davy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.